PITTSBURGH, July 1, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, t

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well ToleratedVR-205 Efficacy and Sa

VR-205 Met Primary Endpoint and Key Secondary Endpoints and Was Well Tolerated VR-205 Efficacy and S

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Dru

U.S. officials discussed possible SSRI restrictions as RFK Jr. unveiled a broader push to reduce ant

JP Morgan analyst Chris Schott maintains Viatris (NASDAQ:VTRS) with a Neutral and raises the pric

Truist Securities analyst Srikripa Devarakonda maintains Viatris (NASDAQ:VTRS) with a Buy and rai

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Viatris (NASDAQ:VTRS) affirms FY2026 Adj EPS guidance from $2.33-$2.47 to $2.33-$2.47 vs $2.44 analy

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.59 per share which beat the analyst consensu

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Theodora "Doretta

https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men

Investors turn to high-yielding dividend stocks in turbulent markets. Benzinga readers can check ana

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga readers can check analyst

Barclays analyst Glen Santangelo maintains Viatris (NASDAQ:VTRS) with a Overweight and raises the

Collaboration expands access to trusted therapies with discounted cash prices for leading brands inc

Viatris (NASDAQ:VTRS) is looking for FY2026 Adj EPS of $2.33-$2.47 vs $2.49 analyst estimate. sees s

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.57 per share which beat the analyst consensu

FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (

Piper Sandler analyst David Amsellem maintains Viatris (NASDAQ:VTRS) with a Neutral and raises th

Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular DiseasesPITTSBU

Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that the Company will prese

Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR De

Barclays analyst Glen Santangelo initiates coverage on Viatris (NASDAQ:VTRS) with a Overweight ra

These 10 S&P 500 stocks are trading at the lowest forward P/E ratios heading into Black Friday 2

U.S. equities took a breather on Tuesday, stabilizing after Monday's sharp rally as investors aw

Viatris (NASDAQ:VTRS) raises FY2025 Adj EPS guidance from $2.16-$2.30 to $2.25-$2.35 vs $2.29 analys

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.67 per share which beat the analyst consensu

Truist Securities analyst Srikripa Devarakonda initiates coverage on Viatris (NASDAQ:VTRS) with a

The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that

Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades.

FDA approves Amphastar's iron sucrose injection for CKD-associated anemia, with potential for $8

Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector

U.S. stocks traded mixed at midday Wednesday, as investors remained cautious ahead of the Federal Re